Stoke Therapeutics (STOK)
NASDAQ:STOK
Want to see STOK full AI Analyst Report?
STOK Stock Chart & Stats
$37.27
-$0.34(-3.65%)
At close: 4:00 PM EST
$37.27
-$0.34(-3.65%)
Day’s Range― - ―
52-Week Range$9.09 - $40.22
Previous CloseN/A
Volume337.58K
Average Volume (3M)548.71K
Market Cap
$1.83B
Enterprise Value$1.68B
Total Cash (Recent Filing)$343.55M
Total Debt (Recent Filing)$3.42M
Price to Earnings (P/E)―
Beta1.54
Next Earnings
Aug 10, 2026EPS Estimate
-0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.83
Shares Outstanding62,281,654
10 Day Avg. Volume636,975
30 Day Avg. Volume548,706
Financial Highlights & Ratios
PEG Ratio2.94
Price to Book (P/B)5.33
Price to Sales (P/S)10.19
P/FCF Ratio41.85
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue52.22
Enterprise Value/Gross Profit57.78
Enterprise Value/Ebitda-9.40
Forecast
1Y Price Target
$47.83Price Target Upside28.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-3.38
Revenue Forecast (FY)$27.16M
Bulls Say, Bears Say
Bulls Say
Clinical Trial Design And EnrollmentConservative late-stage EMPEROR trial design with defined cognitive and behavior endpoints, together with rapid enrollment and low screen‑failure rates, improves the chance of a clear efficacy readout.
Commercial Valuation And Market PotentialAnalyst-updated net price assumptions and strong physician and payor interest suggest meaningful commercial upside for zorevunersen if clinical benefits are confirmed.
Pipeline Expansion And Platform PotentialInitiation of a first‑in‑human study for STK‑002 and the platform’s ability to upregulate underexpressed genes expand the company’s addressable opportunities beyond a single indication.
Bears Say
Commercial Access And Reimbursement RiskInternational pricing rules and potential most‑favored‑nation arrangements could create unpredictability for royalties and revenues outside the United States.
Data Quality ConcernsOpen‑label proof‑of‑concept data and reliance on adjusted analyses reduce the strength of evidence and leave uncertainty about how broadly observed benefits will apply.
Safety And Program Advancement RiskAdvancement of the STK‑002 program depends on favorable safety, tolerability, and exposure results, creating execution risk if adverse findings occur.
Stoke Therapeutics News
STOK FAQ
What was Stoke Therapeutics’s price range in the past 12 months?
Stoke Therapeutics lowest stock price was $9.09 and its highest was $40.22 in the past 12 months.
What is Stoke Therapeutics’s market cap?
Stoke Therapeutics’s market cap is $1.83B.
When is Stoke Therapeutics’s upcoming earnings report date?
Stoke Therapeutics’s upcoming earnings report date is Aug 10, 2026 which is in 77 days.
How were Stoke Therapeutics’s earnings last quarter?
Stoke Therapeutics released its earnings results on May 07, 2026. The company reported -$0.79 earnings per share for the quarter, beating the consensus estimate of -$0.808 by $0.018.
Is Stoke Therapeutics overvalued?
According to Wall Street analysts Stoke Therapeutics’s price is currently Undervalued.
Does Stoke Therapeutics pay dividends?
Stoke Therapeutics does not currently pay dividends.
What is Stoke Therapeutics’s EPS estimate?
Stoke Therapeutics’s EPS estimate is -0.77.
How many shares outstanding does Stoke Therapeutics have?
Stoke Therapeutics has 62,281,654 shares outstanding.
What happened to Stoke Therapeutics’s price movement after its last earnings report?
Stoke Therapeutics reported an EPS of -$0.79 in its last earnings report, beating expectations of -$0.808. Following the earnings report the stock price went up 0.305%.
Which hedge fund is a major shareholder of Stoke Therapeutics?
Currently, no hedge funds are holding shares in STOK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Stoke Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$47.83 (28.34% Upside)
$47.83 (28.34% Upside)
Blogger Sentiment
Bullish
STOK Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 41.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $552.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.8%
Last 30 Days ▼ 6.9%
Last 30 Days ▼ 6.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
208.84%
12-Months-Change
Fundamentals
Return on Equity
-48.84%
Trailing 12-Months
Asset Growth
8.94%
Trailing 12-Months
Company Description
Stoke Therapeutics
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
STOK Company Deck
STOK Earnings Call
Q1 2026
0:00 / 0:00
STOK Stock 12 Month Forecast
Average Price Target
$47.83
▲(28.34% Upside)
Technical Analysis
Syndax Pharmaceuticals
―
Xeris Pharmaceuticals
―
―
Rapport Therapeutics, Inc.
―
Sionna Therapeutics, Inc.
―
Ownership Overview
34.67% Insiders
15.88% Mutual Funds
16.22% Other Institutional Investors
19.57% Public Companies and
Individual Investors